

Methotrexate  
Essential medicine status  
General description

INN

Methotrexate

ATC codes

[L01BA01](#) [L04AX03](#)

Medicine type

Chemical agent

EML status history

First added in 1977 ([TRS 615](#)) for [Unspecified malignant neoplasms of ill-defined or unspecified sites](#)

Added in 1997 ([TRS 882](#)) for [Rheumatoid arthritis, serology unspecified](#)

Added in 2011 ([TRS 965](#)) for [Juvenile idiopathic arthritis](#)

Added in 2015 ([TRS 994](#)) for [Malignant neoplasms of breast](#)

Added in 2015 ([TRS 994](#)) for [Malignant trophoblastic neoplasms of placenta](#)

Added in 2015 ([TRS 994](#)) for [Osteosarcoma of bone and articular cartilage of unspecified sites](#)

Added in 2015 ([TRS 994](#)) for [Lymphoid leukaemia, not elsewhere classified](#)

Added in 2015 ([TRS 994](#)) for [Acute myeloid leukaemia with recurrent genetic abnormalities](#)

Removed in 2015 ([TRS 994](#)) for [Unspecified malignant neoplasms of ill-defined or unspecified sites](#)

Added in 2021 ([TRS 1035](#)) for [Burkitt lymphoma including Burkitt leukaemia](#)

Added in 2023 ([TRS 1049](#)) for [Anaplastic large cell lymphoma, ALK-positive](#)

Added in 2023 ([TRS 1049](#)) for [Anaplastic large cell lymphoma, ALK-negative](#)

Added in 2023 ([TRS 1049](#)) for [Langerhans cell histiocytosis](#)

Added in 2023 ([TRS 1049](#)) for [Psoriasis of unspecified type](#)

Application rejected in 2023 ([TRS 1049](#)) for [Crohn disease site](#)

Application rejected in 2023 ([TRS 1049](#)) for [Psoriatic arthritis](#)

Wikipedia

[Methotrexate](#)

DrugBank

[Methotrexate](#)

Recommendations

Section

Cytotoxic medicines

- Parenteral > General injections > IV: 50 mg in vial (as sodium salt); 50 mg per 2 mL; 1000 mg per 10 mL concentrated injection
- Oral > Solid: 2.5 mg (as sodium salt)
- Parenteral > General injections > IV: 50 mg in vial (as sodium salt)

Indications

[Malignant neoplasms of breast](#) [Malignant trophoblastic neoplasms of placenta](#) [Osteosarcoma of bone and articular cartilage of unspecified sites](#) [Lymphoid leukaemia, not elsewhere classified](#) [Acute myeloid leukaemia with recurrent genetic abnormalities](#) [Unspecified malignant neoplasms of ill-defined or unspecified sites](#) [Burkitt lymphoma including Burkitt leukaemia](#) [Anaplastic large cell lymphoma, ALK-positive](#) [Anaplastic large cell lymphoma, ALK-negative](#) [Langerhans cell histiocytosis](#)

Section

Disease-modifying anti-rheumatic drugs (DMARDs)

- Oral > Solid > tablet: 2.5 mg (as sodium salt)

Indications

[Rheumatoid arthritis, serology unspecified](#)

Section

Medicines for juvenile joint diseases

- Oral > Solid > tablet: 2.5 mg (as sodium salt)

Indications

[Juvenile idiopathic arthritis](#)

Section

Dermatological medicines > Medicines affecting skin differentiation and proliferation

- Oral > Solid > tablet: 2.5 mg (as sodium salt); 10 mg (as sodium salt)

Indications

[Psoriasis of unspecified type](#)

Section

Immunomodulators for non-malignant disease

- Parenteral > General injections > SC: pre-filled syringe in multiple strengths

Indications

[Crohn disease site](#) [Psoriatic arthritis](#)